Indoco Remedies reported a ₹79.3 million net loss in Q2 despite ₹4.72 billion in revenue. Rising costs and weak export performance impacted profitability. Domestic sales held steady, but international challenges weighed on results. The company aims to recover through innovation and new product launches in the upcoming quarters.
Indoco Remedies Ltd reported a consolidated net loss of ₹79.3 million for the September quarter, despite generating ₹4.72 billion in revenue from operations. The pharmaceutical company faced margin pressures and muted demand in key segments, leading to a disappointing bottom line.
Key highlights:
-
Revenue from operations stood at ₹4.72 billion, reflecting steady topline performance amid challenging market conditions.
-
Net loss of ₹79.3 million marks a reversal from previous profitable quarters, driven by higher input costs and subdued export demand.
-
Operational expenses and R&D investments continued to weigh on profitability, as the company maintained its focus on long-term growth.
-
Domestic formulations remained stable, but international business faced headwinds due to regulatory delays and pricing pressures.
Management emphasized its commitment to innovation and portfolio expansion, noting that several new product launches are in the pipeline. Analysts suggest that while the revenue base remains solid, cost optimization and export recovery will be crucial for a turnaround in the coming quarters.
Sources: Moneycontrol, Livemint, Indoco Remedies Investor Relations